Literature DB >> 4025011

Prolonged severe cholestasis induced by oxacillin derivatives. A report on two cases.

P Tauris, N F Jørgensen, C M Petersen, K Albertsen.   

Abstract

Two patients with osteomyelitis who developed reversible cholestatic jaundice during treatment with oxacillin derivatives are described. The clinical course as well as the biochemical pattern and the investigation of liver biopsy specimens enabled us to establish the diagnoses of drug-induced canalicular and hepatocanalicular cholestasis.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4025011     DOI： 10.1111/j.0954-6820.1985.tb03264.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN： 0001-6101


  5 in total

1.  Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.

Authors:  Stefan Russmann; James A Kaye; Susan S Jick; Hershel Jick
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

2.  Updated study on risk of cholestatic liver disease and flucloxacillin.

Authors:  Lin Li; Hershel Jick; Susan S Jick
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 3.  Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic?

Authors:  B M Devereaux; D H Crawford; P Purcell; L W Powell; H P Roeser
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 4.  Nafcillin-associated hepatotoxicity. Report of a case and review of the literature.

Authors:  M E Presti; C G Janney; B A Neuschwander-Tetri
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

5.  Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (augmentin)

Authors:  B H Stricker; J W Van den Broek; J Keuning; W Eberhardt; H G Houben; M Johnson; A P Blok
Journal:  Dig Dis Sci       Date:  1989-10       Impact factor: 3.199
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.